Gavin S. Bennett
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates.
Journal: Expert opinion on investigational drugs
Published: June 04, 2026
Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates.
Journal: Journal of translational medicine
Published: October 27, 2025
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 04, 2024
Bioanalysis of the Bicycle® toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry.
Journal: Bioanalysis
Published: December 13, 2023
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Journal: Molecular cancer therapeutics
Published: November 05, 2021
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads.
Journal: Journal of medicinal chemistry
Published: March 24, 2020
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528.
Journal: Molecular cancer therapeutics
Published: November 28, 2019
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
Journal: Journal of medicinal chemistry
Published: March 09, 2018
Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors.
Journal: Cancer research
Published: February 10, 2018
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.
Journal: ACS medicinal chemistry letters
Published: April 08, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026